NEUROCRINE BIOSCIENCES INC Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
NEUROCRINE BIOSCIENCES INC (NBIX) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-09.
Discontinued › Notes › Income Taxes
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2024-02-09
- NEUROCRINE BIOSCIENCES INC unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $0.00.
- NEUROCRINE BIOSCIENCES INC unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- NEUROCRINE BIOSCIENCES INC unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2021 was $1.70M, a 54.55% increase from fiscal 2020.
- NEUROCRINE BIOSCIENCES INC unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2020 was $1.10M, a 57.14% increase from fiscal 2019.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month as first filed |
|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-09 | |
| 2022-12-31 | $0.00 10-K · filed 2024-02-09 | |
| 2021-12-31 | $1.70M 10-K · filed 2024-02-09 | |
| 2020-12-31 | $1.10M 10-K · filed 2023-02-09 | |
| 2019-12-31 | $700.00K 10-K · filed 2022-02-11 | $657.00K 10-K · filed 2020-02-07 |
| 2018-12-31 | $400.00K 10-K · filed 2021-02-05 | $457.00K 10-K · filed 2019-02-08 |
| 2017-12-31 | $0.00 10-K · filed 2019-02-08 | |
| 2016-12-31 | $1.43M 10-K · filed 2019-02-08 | |
| 2015-12-31 | $0.00 10-K · filed 2018-02-13 | |
| 2014-12-31 | $0.00 10-K · filed 2017-02-14 | |
| 2013-12-31 | $0.00 10-K · filed 2016-02-11 | |
| 2012-12-31 | $164.00K 10-K · filed 2015-02-09 | |
| 2011-12-31 | $80.00K 10-K · filed 2014-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |